Vertex Appoints Charles Wagner as Chief Financial Officer | Business Wire
Vertex today announced the appointment of Charles Wagner as Executive Vice President and Chief Financial Officer, effective April 10, 2019.
Charles River Laboratories and Toxys Enter Agreement to Offer ToxTracker® in...
Charles River and Toxys have entered into an agreement to offer access to ToxTracker® in North America.
U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with...
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved both VYNDAQEL® (tafamidis meglumine) and VYNDAMAX
PharmaCyte Biotech Announces Publication of United States Patent Application for Cancer...
PharmaCyte Biotech announces publication of U.S. patent application for cancer therapies.
DowDuPont Board Approves Separation Of DowDuPont’s Materials Science Division
DowDuPont (DWDP) said that its board has approved the separation of DowDuPont's Materials Science Division, which will become the new Dow on April 1. In connection with the separation, the DowDuPont board of directors declared a pro rata dividend of all of the outstanding shares of common stock of Dow Inc.
Boston Scientific Exercises Option to Acquire Millipede, Inc.
MARLBOROUGH, Mass., Dec. 27, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire th
Sun Pharma Launches Ready-to-Infuse INFUGEM in the U.S. | Business Wire
Sun Pharma launches ready-to-infuse INFUGEM - the first and only chemotherapy product in a premixed, ready-to-infuse formulation - in the US.
Pfizer Receives Positive CHMP Opinion for Vizimpro® (dacomitinib) for the First-line...
Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive op
Takeda Simplifies Portfolio and Accelerates Deleveraging Through Two Divestitures | Business...
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into agreements to divest its Xiidra® (lifite